Amendments to the Claims

Claim 1. (Original) A compound of the formula:



wherein:

W represents:



(a)

,



(b)

,



(c)

or



(d)

;

X represents O or S;

Y represents -C(=O)-, -CH(OH)-, $-CH_2-$, S, SO, or SO_2;

------- represents a single or a double bond;

n is 1, 2, 3 or 4;

R^{1a}, R^{1b}, R^{1c}, R^{1d}, and R^2 are each independently H, F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, $-NR_7R_8$, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_3 represents H, OH, hydroxy(C_1-C_6)alkyl, C_1-C_6 alkyl, or C_1-C_6 alkoxy;

R_4 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or heterocycle substituted with from 1 to 3

substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;
R_5 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl,C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or C_3-C_8 cycloalkyl substituted with C_1-C_4 alkyl;
R_{6a} and R_{6b} are each independently H or C_1-C_3 alkyl;
R_7 and R_8 are each independently H, C_1-C_6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;
or a pharmaceutically acceptable salt thereof.

Claim 2. (Original) A compound according to claim 1 wherein X is O.

Claim 3. (Original) A compound according to claim 1 wherein X is S.

Claim 4. (Previously amended) A compound according to claim 1 wherein R_2 is H.

Claim 5. (Previously amended) A compound according to claim 1 wherein n is 2.

Claim 6. (Previously amended) A compound according to claim 1 wherein R_3 is H.

Claim 7. (Previously amended) A compound according to claim 1 wherein R_3 is methyl.

Claim 8. (Previously amended) A compound according to claim 1 wherein R_4 is 2-pyridyl.

Claim 9. (Previously amended) A compound according to claim 1 wherein ------ is a double bond.

Claim 10. (Previously amended) A compound according to claim 1 wherein Y is –CO-.

Claim 11. (Original) A compound which is selected from the group consisting of:

a) 4-(6-benzo(b)thiophene-1,2,3,6-tetrahydropyridyl)-1-cyclohexyl-2-(2-pyridyl) butan-1-one;

b) 4-(5-benzo(b)thiophene-1,2,3,6-tetrahydropyridyl)-1-cyclohexyl-2-(2-pyridyl) butan-1-one;

c) 4-(2-benzo(b)thiophene-1,2,3,6-tetrahydropyridyl)-1-cyclohexyl-2-(2-pyridyl) butan-1-one; and

d) 4-(3-benzo(b)thiophene-1,2,3,6-tetrahydropyridyl)-1-cyclohexyl-2-(2-pyridyl) butan-1-one; or a pharmaceutically acceptable salt thereof.

Claim 12. (Original) A method of inhibiting the reuptake of serotonin and antagonizing the 5-HT_{1A} receptor which comprises administering to a subject in need of such treatment an effective amount of a compound of the formula:



wherein:

W represents:



(a)

,



(b)

,



(c)

or



(d)

;

X represents O or S;

Y represents -C(=O)-, -CH(OH)-, $-CH_2-$, S, SO, or SO_2;

------- represents a single or a double bond;

n is 1, 2, 3 or 4;

R^{1a}, R^{1b}, R^{1c}, R^{1d}, and R^2 are each independently H, F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, $-NR_7R_8$, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_3 represents H, OH, hydroxy(C_1-C_6)alkyl, C_1-C_6 alkyl, or C_1-C_6 alkoxy;

R_4 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_5 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6

alkyl,C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or C_3-C_8 cycloalkyl substituted with C_1-C_4 alkyl;

R_{6a} and R_{6b} are each independently H or C_1-C_3 alkyl;

R_7 and R_8 are each independently H, C_1-C_6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

or a pharmaceutically acceptable salt thereof.

Claim 13. (Original) A method of potentiating the action of a serotonin reuptake inhibitor comprising administering to a subject in of such treatment a compound formula:



wherein:

W represents:



(a)

,



(b)

,



(c)

or



(d)

;

X represents O or S;

Y represents -C(=O)-, -CH(OH)-, $-CH_2-$, S, SO, or SO_2;

------- represents a single or a double bond;

n is 1, 2, 3 or 4;

R^{1a}, R^{1b}, R^{1c}, R^{1d}, and R^2 are each independently H, F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, -NR_7R_8, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_3 represents H, OH, hydroxy(C_1-C_6)alkyl, C_1-C_6 alkyl, or C_1-C_6 alkoxy;

R_4 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_5 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl,C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or C_3-C_8 cycloalkyl substituted with C_1-C_4 alkyl;

R_{6a} and R_{6b} are each independently H or C_1-C_3 alkyl;

R_7 and R_8 are each independently H, C_1-C_6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

or a pharmaceutically acceptable salt thereof.

Claim 14. (Original) A method of treating depression comprising administering to a subject in need thereof an effective amount of a compound of formula:



wherein:

W represents:



(a)

,



(b)

,



(c)

or



(d)

;

X represents O or S;

Y represents -C(=O)-, -CH(OH)-, $-CH_2-$, S, SO, or SO_2;

------- represents a single or a double bond;

n is 1, 2, 3 or 4;

R^{1a}, R^{1b}, R^{1c}, R^{1d}, and R^2 are each independently H, F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, $-NR_7R_8$, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_3 represents H, OH, hydroxy(C_1-C_6)alkyl, C_1-C_6 alkyl, or C_1-C_6 alkoxy;

R_4 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

R_5 represents aryl, heterocycle, C_3-C_8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6

alkyl,C_1-C_6 alkoxy, hydroxy(C_1-C_6)alkyl, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN; or C_3-C_8 cycloalkyl substituted with C_1-C_4 alkyl;

R_{6a} and R_{6b} are each independently H or C_1-C_3 alkyl;

R_7 and R_8 are each independently H, C_1-C_6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C_1-C_6 alkyl, C_1-C_6 alkoxy, halo(C_1-C_6)alkyl, phenyl, NO_2, NH_2, or CN;

or a pharmaceutically acceptable salt thereof.

Claim 15 (Previously amended). A pharmaceutical composition comprising an effective amount of a compound as claimed in claim 1 in combination with a pharmaceutical acceptable carrier, diluent or excipient.

Please cancel claims 16-20.